GWOXI Stem Cell Secures Invention Patent for Diabetes Cell Therapy
Gwo Xi Stem Cell’s diabetes therapy candidate “GXIPC1®” has successfully secured patents in the United States, China, and Taiwan (illustrative image).
Gwo Xi Stem Cell, a leading stem cell therapy company in Taiwan, has secured patents in the United States (Patent No. US12,195,754), China (Patent No. CN113736725), and Taiwan (Patent No. I776368) for its innovation titled “Cell differentiation medium composition, high secretion insulin-producing cells and preparation method thereof.” This milestone strengthens the company’s intellectual property portfolio for diabetes treatment using high-insulin-secreting cells and their production methods, creating favorable conditions to accelerate the progress toward commercialization.
Globally, one in four adults is at risk of developing diabetes. To raise awareness about its prevention and treatment, the International Diabetes Federation has designated November 14 as World Diabetes Day. According to the Health Promotion Administration of Taiwan, data from the 2019–2023 National Nutrition and Health Survey indicate a 12.8% prevalence rate of diabetes among adults over 20 years old, with cases showing a trend toward younger populations. Early-stage diabetes often shows no obvious symptoms, causing many individuals to overlook the disease until signs such as excessive hunger (polyphagia), excessive thirst (polydipsia), frequent urination (polyuria), or unexplained weight loss appear—by which time the optimal window for early intervention and potential reversal is often missed.
Gwo Xi Stem Cell continues to advance stem cell medicines and related technologies (illustrative image).
From a pathological perspective, the major types of diabetes include Type 1, Type 2, and gestational diabetes. Without treatment, hyperglycemia can lead to severe complications such as cardiovascular disease, stroke, chronic kidney disease, foot ulcers, neuropathy, vision impairment, and cognitive decline. “Cell differentiation medium composition, high secretion insulin-producing cells and preparation method thereof” addresses these challenges by enabling transplanted high-insulin-secreting cells to resist phagocytosis by macrophages, thereby prolonging insulin secretion and improving in vivo survival rates. This innovation provides a novel therapeutic approach for endocrine disorders caused by insufficient insulin secretion or impaired insulin utilization.
Based in Taiwan, Gwo Xi Stem Cell leverages patent portfolio to build niche markets and drive global expansion (illustrative image).
Gwo Xi Stem Cell is renowned for its strong innovation capabilities experienced research team, and reliable technological platform. Its expertise covers the entire cell therapy industry chain. With a strong focus on innovation and R&D investment, Gwo Xi Stem Cell consistently delivers cutting-edge results. Leveraging its R&D base in Taiwan and intellectual property strategy, the company aims to create new niche markets and expand market through strategic partnerships.